Protease 2A induces stress granule formation during coxsackievirus B3 and enterovirus 71 infections
© Wu et al.; licensee BioMed Central Ltd. 2014
Received: 12 April 2014
Accepted: 26 October 2014
Published: 20 November 2014
Stress granules (SGs) are granular aggregates in the cytoplasm that are formed under a variety of stress situations including viral infection. Previous studies indicate that poliovirus, a member of Picornaviridae, can induce SG formation. However, the exact mechanism by which the picornaviruses induce SG formation is unknown.
The localization of SG markers in cells infected with coxsackievirus B3 (CVB3) or enterovirus 71 (EV71) and in cells expressing each viral protein was determined via immunofluorescence assays or plasmid transfection. Eight plasmids expressing mutants of the 2A protease (2Apro) of CVB3 were generated using a site-directed mutagenesis strategy. The cleavage efficiencies of eIF4G by CVB3 2Apro and its mutants were determined via western blotting assays.
In this study, we found that CVB3 infection induced SG formation, as evidenced by the co-localization of some accepted SG markers in viral infection-induced granules. Furthermore, we identified that 2Apro of CVB3 was the key viral component that triggered SG formation. A 2Apro mutant with the G122E mutation, which exhibited very low cleavage efficiency toward eIF4G, significantly attenuated its capacity for SG induction, indicating that the protease activity was required for 2Apro to initiate SG formation. Finally, we observed that SGs also formed in EV71-infected cells. Expression of EV71 2Apro alone was also sufficient to cause SG formation.
Both CVB3 and EV71 infections can induce SG formation, and 2Apro plays a crucial role in the induction of SG formation during these infections. This finding may help us to better understand how picornaviruses initiate the SG response.
KeywordsStress granule 2A protease Coxsackievirus B Enterovirus 71
Stress granules (SGs) are granular aggregates formed in the cytoplasm of eukaryotic cells exposed to a variety of environmental stress conditions, e.g., heat shock, UV irradiation, hypoxia, endoplasmic reticulum stress, and viral infection ,. SGs typically contain translationally silent mRNAs, 40S ribosomal subunits, eukaryotic initiation factors (eIFs) such as eIF4E, eIF4G, eIF4A, eIF4B, eIF3, and eIF2, and RNA-binding proteins (RBPs), including poly(A)-binding protein (PABP1), the embryonic lethal abnormal vision (ELAV) Hu protein (HuR), polysomal ribonuclease 1 (PMR-1), tristetraprolin (TTP), T-cell-restricted intracellular antigen 1 (TIA1), TIA-1-related protein (TIAR), fragile X mental retardation protein (FMRP), and Ras-Gap SH3-binding protein (G3BP1) ,. Among these recruited proteins, HuR, TIA1, and G3BP1 can act as markers of SGs –.
Numerous viruses have been shown to interact with SGs with different effects –. Some viruses induce stable SG formation during infection, e.g., respiratory syncytial virus (RSV). Some viruses, e.g., mammalian orthoreoviruses (MRV), Semliki Forest viruses (SFV), and hepatitis C viruses (HCV) have been shown to induce SG formation but to disassemble these granules as infection proceeds. Poliovirus (PV) induces SG formation early during infection and later inhibits SGs through the viral 3Cpro-mediated cleavage of G3BP1. Meanwhile, TIA1-containing foci devoid of other SG-defining components, such as initiation factors and most mRNAs were observed late post-infection. Some viruses, e.g., West Nile virus (WNV), dengue virus (DV), rhesus rotavirus (RRV), type 1 human T-cell leukemia viruses (HTLV-1), and human immunodeficiency viruses (HIV) were found to be able to suppress SG formation –. Cardioviruses with mutant leader (L) proteins, such as Theiler’s murine encephalomyelitis virus (TMEV), encephalomyocarditis virus (EMCV) and Saffold virus (SAFV) induce SG formation throughout the infection, while expression of the L protein during infection efficiently blocks SG formation. Similarly, influenza A virus (IAV) infection fails to induce SGs unless viruses with NS1 mutations are used –. In some cases, SGs play an important role in host antiviral defense, e.g., IAV, MRV and vaccinia virus (VV). However, SGs induced by RSV can promote virus replication –.
Group B coxsackieviruses (CVBs) are the major pathogens of human viral myocarditis and dilated cardiomyopathy ,. Enterovirus 71 (EV71) is the major pathogen of human hand, foot, and mouth disease (HFMD) . Both CVBs and EV71 belong to the enterovirus genus of the Picornaviridae family. The picornavirus genome is a ~7.0-kb-to-8.5-kb single-stranded positive-sense RNA (+ssRNA) that is composed of a single open reading frame (ORF) and two untranslated regions (UTRs) at its 5’ and 3’ flanks. The genome can act as an mRNA encoding a polyprotein that is proteolytically processed by viral proteinases into structural and nonstructural proteins . Picornaviruses induce multiple alterations in host cells to facilitate its replication. Suppressing cellular biosynthesis by viral proteinases 2A (2Apro) and 3C (3Cpro) is one of the most notable alterations –. Upon the cleavage of eIF4G, eIF5B, and PABP by 3Cpro and 2Apro, picornaviruses can shut off cap-dependent translation and terminate cellular biosynthesis –. In addition, through the cleavage of nuclear pore complex proteins (Nups), 2Apro can alter RNA and protein trafficking between the nucleus and cytoplasm . A recent report shows that 2Apro of PV, a member of Picornaviridae, can cause a dramatic nuclear-cytoplasm re-localization of SRp20, a cellular splicing factor that is also defined as an IRES trans-acting factor (ITAF) .
Recent studies indicate that PV induces unique SGs in infected cells –. The PV-induced SGs contain certain components that do not localize to SGs induced by oxidative stress, e.g., Sam68 and SRp20 ,. However, the exact mechanism by which the picornavirus induces SG formation is unknown. In this study, we confirmed that CVB type 3 (CVB3) and EV71 also induce SG formation. We found that 2Apro plays a crucial role in SG induction because 2Apro alone is sufficient to trigger SG formation. Our findings may help us to better understand the mechanism by which picornaviruses initiate SG formation.
CVBinfection induces SG formation
Using an anti-HuR or anti-G3BP1 antibody, we found that HuR was predominantly localized in the nucleus of the mock-infected cells, but it re-localized to the cytoplasmic granules after both Ars treatment and CVB3 infection (Figure 1A). G3BP1 was distributed evenly in the cytoplasm of the mock-infected cells but formed granules in the CVB3-infected cells at 3 h p.i. but the G3BP1-positive granules dispersed at 6 h p.i. (Figure 1B). EGFP-TIA1 and HuR were co-localized in the granules in Ars-treated and CVB3-infected cells (Figure 1A). G3BP1 was also co-localized with EGFP-TIA1 in the granules of Ars-treated (data not shown) and CVB3-infected cells (Figure 1B).
Furthermore, in HeLa cells co-transfected with pEGFP-eIF4G and pmCherry-HuR, both mCherry-HuR and EGFP-eIF4G re-located from the nucleus to the cytoplasmic granules after CVB3 infection (MOI = 10) for 3 h (Figure 1C). We also noticed that the SGs contained HuR but no eIF4G at 6 h p.i. (Figure 1C). These data demonstrate that CVB3 induced typical SGs.
2Apro is the key protein that triggers SG formation
By monitoring the endogenous HuR distribution using the anti-HuR antibody, a similar result was observed in cells only transfected with the viral protein-expressing plasmids (Figure 2B). Identically, G3BP1 detection showed that G3BP1 was distributed in cytoplasmic granules only in the cells expressing 2Apro (Figure 2C). These results imply that 2Apro is the key viral component that triggers SG formation during CVB3 infection.
The protease activity is necessary for 2Apro to trigger SG formation
The eIF4G cleavage activity obtained with different variants of CVB3 2A pro
eIF4G cleavage activity*
+ + +
+ + +
+ + +
+ + +
+ + +
+ + +
To determine whether the proteinase activity of 2Apro is required for SG formation, HeLa cells were co-transfected with pmCherry-HuR and each of the mutant-expressing plasmids. We found that only a few SGs were formed in cells expressing 2AG122E. In contrast, there were abundant SGs formed in the cells expressing other 2Apro mutants (Figure 4A). Quantitative analysis of these data revealed that only 7% (±3%) of EGFP-2AG122E-expressing cells contained SGs and over 90% of cells expressing the other 2A mutants remained positive for SGs. Similar results were observed for G3BP1 as the SG marker (Figure 4B). Therefore, we concluded that the protease activity was required for 2Apro to induce SGs.
EV71 and its 2Apro also induce SG formation
The interaction between viruses and host cells is critical for understanding the pathogenesis of viral infections. SG formation is one of the remarkable cellular events when cells sense an unfavorable stimulation ,. Multiple viruses interact with SGs in different ways –. It has been reported that PV can induce SG formation. CVB3, EV71, and PV are members of the genus Enterovirus; however, they cause completely different types of diseases ,,. In this study, we found that CVB3 and EV71 could efficiently induce SG formation. The 2Apro of both viruses were identified as the key for triggering SG formation. Our findings may help us to better understand the mechanism by which the picornaviruses initiate SG formation.
According to previous studies, TIA1, HuR, G3BP1, and eIF4G were chosen as the SG markers for our observations. TIA1 and HuR have been shown to be constantly recruited to SGs during PV infection, while G3BP1 and eIF4G can be detected in SGs at the early stage of the PV infection, but not later –. To facilitate observing the effect of virus on SG formation, we first constructed a HeLaEGFP-TIA1 cell line constitutively expressing TIA1. EGFP-TIA1 was distributed in cytoplasmic granules in CVB3- and EV71-infected HeLaEGFP-TIA1 cells (Figures 1 and 4). The granules were further confirmed as SGs because HuR, G3BP1, and eIF4G were also found in the granules (Figure 1). The SGs emerged as early as 3 h after the cells were infected with CVB3 or EV71 (MOI = 10) (Figures 1 and 5), suggesting that CVB3 and EV71 may efficiently induce SG formation. We also observed that G3BP1 and eIF4G were not localized to the SGs at the late stages of CVB3 or EV71 infection (data not shown), which was similar to the results during PV infection ,. Thus, it is likely that SG formation may be a common feature in the response to picornavirus infections.
It would be interesting to know how picornaviruses initiate SG formation. SG formation may be triggered directly by a single viral component, or it could be indirectly induced by the distorted cellular environment when the picornavirus infections occur. Upon observation of the cellular response to every CVB3 protein, SGs traced by mCherry-HuR or endogenous HuR could only be viewed in cells expressing 2Apro (Figure 2). HuR dominantly localizes in the nucleus. It is known that 2Apro can disturb the nucleus-cytoplasm trafficking of macromolecules through cleaving nuclear pore proteins . Thus, the translocalization of HuR may be a consequence of the nucleus-cytoplasm trafficking malfunction caused by 2Apro. For this reason, we validated our observation using the cytoplasmic SG marker G3BP1. Interestingly, G3BP1-labeled SGs could also only be viewed in cells expressing 2Apro (Figure 2).
To further verify the role of 2Apro in SG formation, we generated eight 2Apro mutants based on studies of PV 2Apro ,,. Among them, the protease activity of 2AG122E was attenuated shown by measuring the cleavage efficiency of eIF4G. Accordingly, 2AG122E did not induce SG formation, indicating that the protease activity was required for 2Apro to trigger SG formation (Figure 4). Our results suggest that 2Apro may be the key viral protein of CVB3 and EV71 to induce SG formation.
The role of 2Apro in SG formation may be similar in PV infection. A recent study showed that PV infection could cause the redistribution of SRp20, a nucleocytoplasmic shuttling splicing factor . The ectopic expression of PV 2Apro was sufficient to cause the re-localization of SRp20 from the nucleus to the cytoplasmic granules . A later study demonstrated that SRp20 could co-localize with TIA1 in the cytoplasmic granules of PV-infected cells, suggesting that SRp20 might also be a SG component . These observations provide extra evidence for the role of 2Apro in SG formation during picornavirus infections.
In summary, our findings help us to better understand the mechanism by which picornaviruses initiate SG formation in infected cells. However, the cellular components that 2Apro targets to trigger SG formation remain unknown. Further study is needed to identify these targets to elucidate this cellular event.
In this study, we demonstrated that both CVB3 and EV71 infections can induce SG formation and that 2Apro plays a crucial role in the induction of SG formation during these infections. The protease activity was necessary for 2Apro to trigger SG formation. This novel finding may help us to better understand the mechanism by which picornaviruses initiate the SG response.
Cell lines and viruses
HeLa cells were grown in Dulbecco’s modified Eagle medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 8% (growth medium) or 5% (maintaining medium) fetal bovine serum (FBS) (Biological Industries Israel). A HeLa cell line stably expressing EGFP-TIA1 was established as described previously . HeLa cells were cultured in 12-well plates to approximately 60% confluence and transfected with the plasmid pEGFP-TIA1 using Lipofectamine 2000 (Invitrogen). Cells were then grown in medium containing G418 (500 μg/ml). We replaced the culture medium every 2 days until colonies were observed. We acquired the stable cell line HeLaEGFP-TIA1 through 8 weeks of selection. HeLaEGFP-TIA1 cells stably expressing EGFP-TIA1 were grown in DMEM containing 10% FBS and 500 μg/ml G418. The CVB3 Woodruff strain was passaged in HeLa cells and titered by plaque assays as described previously . The EV71 BrCr strain was passaged in Vero cells and titrated using the 50% tissue culture infective dose (TCID50) assay as described in our previous research .
The plasmid expressing EGFP-tagged TIA1 or eIF4G was constructed in our laboratory. First, the EGFP-coding sequence was obtained from pEGFP-N1 (Clontech, Mountain View, CA) by polymerase chain reaction (PCR). The pcDNA3.1 (Invitrogen) and EGFP amplicons were digested by Nhe I and Hind III and then ligated at 16°C overnight with T4 ligase. The obtained plasmid was designated as pEGFP-C1. TIA1 and eIF4G cDNAs were amplified by reverse transcription PCR (RT-PCR) from the RNA extracts prepared from HeLa cells using TRIzol reagents (Invitrogen) and then cloned into pEGFP-C1. The resulting plasmids were designated as pEGFP-TIA1 and pEGFP-eIF4G, respectively. Similarly, the pmCherry-HuR plasmid, encoding a fusion protein of HuR and red fluorescence protein mCherry, was constructed based on pmCherry-C1 (Clontech). The plasmids were confirmed by DNA sequencing. The primers for the amplifications are listed in Additional file 1: Table S1.
Nine plasmids expressing EGFP-tagged VP1, VP4-VP2-VP3, 2Apro, 2B, 2C, 3A, 3B, 3Cpro, or 3D of CVB3 were constructed as described previously , and designated as pEGFP-VP1, pEGFP-VP4-3, pEGFP-2A, pEGFP-2B, pEGFP-2C, pEGFP-3A, pEGFP-3B, pEGFP-3C, and pEGFP-3D, respectively. The primers are listed in Additional file 1: Table S2 and Table S3.
Eight mutants of CVB3 2Apro, including 2AD39E, 2AL40F, 2AS67F, 2AY89L, 2AY90L, 2AV120M, 2AG122E and 2AD136N, were generated by overlap PCR. Briefly, to generate 2AD39E, the pEGFP-2A DNA was amplified with 2A sense primer and 2AD39E antisense primer, and with 2AD39E sense primer and 2A antisense primer, respectively (Additional file 1: Table S3). The PCR products were purified and mixed together. The mixture was amplified with 2A sense and antisense primers. The resultant DNA was digested with Hind III and Xba I and inserted into the cloning site of pEGFP-C1. These plasmids were designated as pEGFP-2AD39E, pEGFP-2AL40F, pEGFP-2AS67F, pEGFP-2AY89L, pEGFP-2AY90L, pEGFP-2AV120M, pEGFP-2AG122E, and pEGFP-2AD136N, respectively. The digested fragments were mixed and ligated to pEGFP-C1/Hind III + Xba I. All plasmids were confirmed by DNA sequencing.
For virus infection, HeLa cells were seeded in 24-well plates and grown to approximately 60% confluence. The cells were then co-transfected with 0.1 μg pmCherry-HuR and 0.5 μg pEGFP-C1, or pEGFP-eIF4G using 1 μl Lipofectamine 2000 (Invitrogen) per well. To express the viral proteins, cells were seeded in 24-well plates and grown to approximately 70% confluence. Cells were then co-transfected with 0.3 μg pmCherry-HuR and 0.3 μg plasmid encoding EGFP-tagged CVB3 2Apro, 2B, 2C, 3A, 3B, 3Cpro, 3D, VP1, VP4-VP2-VP3, 2AD39E, 2AL40F, 2AS67F, 2AY89L, 2AY90L, 2AV120M, 2AG122E, or 2AD136N; EV71 2Apro; or the empty vector pEGFP-C1. Five hours later, the culture media were removed and replaced with fresh media. Images were taken using an Axiovert 200 fluorescence microscope (Carl Zeiss, Gottingen, Germany) at 24 h post-transfection. Some cells were seeded in 48-well plates and transfected with plasmid encoding EGFP-tagged CVB3 2Apro, 2AG122E or 3Cpro. Control cells were transfected with pEGFP-C1. After 24 h post-transfection, the cells were fixed for immunofluorescence assay of HuR and G3BP1. To investigate eIF4G cleavage, HeLa cells were transfected with plasmid encoding EGFP-tagged CVB3 2Apro, 2AD39E, 2AL40F, 2AS67F, 2AY89L, 2AY90L, 2AV120M, 2AG122E or 2AD136N. Cells were harvested at 24 h post-transfection. Whole-cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting analysis.
HeLaEGFP-TIA1 cells were mock-infected, or infected with CVB3 or EV71 at a multiplication of infection (MOI) of 10. At 3 h p.i., HeLaEGFP-TIA1 cells were fixed for immunofluorescence assays. HeLa cells, co-transfected with pmCherry-HuR and pEGFP-C1, or pEGFP-eIF4G or pEGFP-eIF4GG681E, were mock-infected or infected with CVB3 (MOI = 10). At 3, 4, or 6 h p.i., the cells were washed once with phosphate-buffered saline (PBS), and processed for imaging using an Axiovert 200 fluorescence microscope.
Arsenite (Ars) treatment
Ars has been widely used as a stimulator of SGs . To induce SGs, cells were treated with sodium arsenite (NaArs) (Sigma-Aldrich, St. Louis, MO) at a concentration of 0.5 mM in growth medium for 30 min.
Following virus infection, Ars treatment, or plasmid transfection as described above, the cells were washed once with PBS and then fixed with 4% paraformaldehyde at room temperature for 30 min. The cells were treated with 0.25% Triton X-100 for 10 min and blocked with PBS containing 1% bovine serum albumin (BSA) for 30 min at room temperature. Cells were then incubated overnight at 4°C with primary antibody diluted in blocking buffer and with secondary antibody for 2 h at room temperature in the dark. G3BP1 was detected via a monoclonal anti-G3BP1 antibody (611126, BD Transduction Labs, San Jose, CA) at a dilution of 1:200 and a CF555-labeled goat anti-mouse secondary antibody (20231, Biotium, Hayward, CA) at a dilution of 1:1000. HuR was detected via a polyclonal antibody (11910-1-AP, Proteintech Group Inc., Chicago, IL) at a dilution of 1:200 and a CF555-labeled anti-rabbit secondary antibody (20232, Biotium) at a dilution of 1:1000. The cells were then washed three times with PBS and stained with Hoechst 33342 (0.4 μg/ml in PBS). Images were taken using an Axiovert 200 fluorescence microscope.
Proteins were extracted from the treated cells using Pierce RIPA Buffer with PMSF cocktail. Approximately 2 μg of the extracted proteins were applied to SDS-PAGE. The separated proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (0.45 μm, Millipore, Billerica, MA), which was blocked with 5% nonfat milk for 2 h at 37°C and incubated with primary antibody overnight at 4°C. A polyclonal rabbit anti-eIF4G antibody (15704-1-AP, Proteintech Group Inc.) was 1:1000 diluted to detect eIF4G; a polyclonal anti-β-actin antibody (sc-130301, Santa Cruz Biotechnology, SantaCruz, CA) was 1:1000 diluted to detect β-actin. After a standard washing, the membrane was incubated with horse radish peroxidase (HRP)-labeled secondary antibody (Zhongshan Goldenbridge Biotech, Beijing, China) for 1 h at room temperature and washed again. The blots were stained using Super Signal kit (Pierce, Rockford, IL) and imaged by a LAS4000 charge-coupled camera (Fujifilm, Tokyo, Japan). The β-actin was employed as a loading control.
SW participated in the design of the study, performed plasmid construction, immunofluorescence assays, and western blotting and drafted the manuscript. YW coordinated the experimental design and helped edit the manuscript. LL performed viral infection and cell transfection. XS participated in the design of the study. TW and XZ performed arsenite treatment. LT, YL and YC performed cell transfection. XL and FZ helped coordinate the experimental design. WZ and ZZ made substantial contributions to the experimental design and coordination. All authors read and approved the final manuscript.
This study was supported by the Natural Science Foundation of China (NSFC) (81271825 to Z. Zhong, 31270198 to W. Zhao, 81101234 to T. Lei, 81101235 to Y. Wang, and 31300144 to T. Wang). We thank the Heilongjiang Provincial Key Laboratory of Pathogens and Immunity, and the Heilongjiang Provincial Science and Technology Innovation Team in Higher Education Institutes for Infection, Harbin Medical University, Harbin 150081, China for technical support.
- Anderson P, Kedersha N: Stress granules. Curr Biol. 2009, 19: R397-R398. 10.1016/j.cub.2009.03.013.PubMedView ArticleGoogle Scholar
- Buchan JR, Parker R: Eukaryotic stress granules: the ins and outs of translation. Mol Cell. 2009, 36: 932-941. 10.1016/j.molcel.2009.11.020.PubMedPubMed CentralView ArticleGoogle Scholar
- Gilks N, Kedersha N, Ayodele M, Shen L, Stoecklin G, Dember LM, Anderson P: Stress granule assembly is mediated by prion-like aggregation of TIA-1. Mol Biol Cell. 2004, 15: 5383-5398. 10.1091/mbc.E04-08-0715.PubMedPubMed CentralView ArticleGoogle Scholar
- von Roretz C, Di Marco S, Mazroui R, Gallouzi IE: Turnover of AU-rich-containing mRNAs during stress: a matter of survival. Wiley Interdiscip Rev RNA. 2011, 2: 336-347. 10.1002/wrna.55.PubMedView ArticleGoogle Scholar
- White JP, Lloyd RE: Regulation of stress granules in virus systems. Trends Microbiol. 2012, 20: 175-183. 10.1016/j.tim.2012.02.001.PubMedPubMed CentralView ArticleGoogle Scholar
- Lloyd RE: How do viruses interact with stress-associated RNA granules?. PLoS Pathog. 2012, 8: e1002741-10.1371/journal.ppat.1002741.PubMedPubMed CentralView ArticleGoogle Scholar
- Valiente-Echeverria F, Melnychuk L, Mouland AJ: Viral modulation of stress granules. Virus Res. 2012, 169: 430-437. 10.1016/j.virusres.2012.06.004.PubMedView ArticleGoogle Scholar
- Borghese F, Michiels T: The leader protein of cardioviruses inhibits stress granule assembly. J Virol. 2011, 85 (18): 9614-9622. 10.1128/JVI.00480-11.PubMedPubMed CentralView ArticleGoogle Scholar
- Langereis MA, Feng Q, van Kuppeveld FJ: MDA5 localizes to stress granules, but this localization is not required for the induction of type I interferon. J Virol. 2013, 87 (11): 6314-6325. 10.1128/JVI.03213-12.PubMedPubMed CentralView ArticleGoogle Scholar
- Knowlton KU: CVB infection and mechanisms of viral cardiomyopathy. Curr Top Microbiol Immunol. 2008, 323: 315-335.PubMedGoogle Scholar
- Fairweather D, Stafford KA, Sung YK: Update on coxsackievirus B3 myocarditis. Curr Opin Rheumatol. 2012, 24: 401-407. 10.1097/BOR.0b013e328353372d.PubMedPubMed CentralView ArticleGoogle Scholar
- Wong SS, Yip CC, Lau SK, Yuen KY: Human enterovirus 71 and hand, foot and mouth disease. Epidemiol Infect. 2010, 138: 1071-1089. 10.1017/S0950268809991555.PubMedView ArticleGoogle Scholar
- Castello A, Alvarez E, Carrasco L: The multifaceted poliovirus 2A protease: regulation of gene expression by picornavirus proteases. J Biomed Biotechnol. 2011, 2011: 369648-10.1155/2011/369648.PubMedPubMed CentralView ArticleGoogle Scholar
- Kuyumcu-Martinez NM, Joachims M, Lloyd RE: Efficient cleavage of ribosome-associated poly(A)-binding protein by enterovirus 3C protease. J Virol. 2002, 76: 2062-2074. 10.1128/jvi.76.5.2062-2074.2002.PubMedPubMed CentralView ArticleGoogle Scholar
- Rassmann A, Henke A, Zobawa M, Carlsohn M, Saluz HP, Grabley S, Lottspeich F, Munder T: Proteome alterations in human host cells infected with coxsackievirus B3. J Gen Virol. 2006, 87: 2631-2638. 10.1099/vir.0.81819-0.PubMedView ArticleGoogle Scholar
- Chau DH, Yuan J, Zhang H, Cheung P, Lim T, Liu Z, Sall A, Yang D: Coxsackievirus B3 proteases 2A and 3C induce apoptotic cell death through mitochondrial injury and cleavage of eIF4GI but not DAP5/p97/NAT1. Apoptosis. 2007, 12: 513-524. 10.1007/s10495-006-0013-0.PubMedView ArticleGoogle Scholar
- de Breyne S, Bonderoff JM, Chumakov KM, Lloyd RE, Hellen CU: Cleavage of eukaryotic initiation factor eIF5B by enterovirus 3C proteases. Virology. 2008, 378: 118-122. 10.1016/j.virol.2008.05.019.PubMedPubMed CentralView ArticleGoogle Scholar
- Fitzgerald KD, Chase AJ, Cathcart AL, Tran GP, Semler BL: Viral proteinase requirements for the nucleocytoplasmic relocalization of cellular splicing factor SRp20 during picornavirus infections. J Virol. 2013, 87: 2390-2400. 10.1128/JVI.02396-12.PubMedPubMed CentralView ArticleGoogle Scholar
- White JP, Cardenas AM, Marissen WE, Lloyd RE: Inhibition of cytoplasmic mRNA stress granule formation by a viral proteinase. Cell Host Microbe. 2007, 2: 295-305. 10.1016/j.chom.2007.08.006.PubMedView ArticleGoogle Scholar
- Piotrowska J, Hansen SJ, Park N, Jamka K, Sarnow P, Gustin KE: Stable formation of compositionally unique stress granules in virus-infected cells. J Virol. 2010, 84: 3654-3665. 10.1128/JVI.01320-09.PubMedPubMed CentralView ArticleGoogle Scholar
- White JP, Lloyd RE: Poliovirus unlinks TIA1 aggregation and mRNA stress granule formation. J Virol. 2011, 85: 12442-12454. 10.1128/JVI.05888-11.PubMedPubMed CentralView ArticleGoogle Scholar
- Fitzgerald KD, Semler BL: Poliovirus infection induces the co-localization of cellular protein SRp20 with TIA-1, a cytoplasmic stress granule protein. Virus Res. 2013, 176: 223-231. 10.1016/j.virusres.2013.06.012.PubMedPubMed CentralView ArticleGoogle Scholar
- Yu SF, Lloyd RE: Identification of essential amino acid residues in the functional activity of poliovirus 2A protease. Virology. 1991, 182: 615-625. 10.1016/0042-6822(91)90602-8.PubMedView ArticleGoogle Scholar
- Barco A, Ventoso I, Carrasco L: The yeast Saccharomyces cerevisiae as a genetic system for obtaining variants of poliovirus protease 2A. J Biol Chem. 1997, 272: 12683-12691. 10.1074/jbc.272.19.12683.PubMedView ArticleGoogle Scholar
- Ventoso I, Barco A, Carrasco L: Mutational analysis of poliovirus 2Apro. Distinct inhibitory functions of 2Apro on translation and transcription. J Biol Chem. 1998, 273: 27960-27967. 10.1074/jbc.273.43.27960.PubMedView ArticleGoogle Scholar
- Mueller S, Wimmer E, Cello J: Poliovirus and poliomyelitis: a tale of guts, brains, and an accidental event. Virus Res. 2005, 111: 175-193. 10.1016/j.virusres.2005.04.008.PubMedView ArticleGoogle Scholar
- Wu S, Lin L, Zhao W, Li X, Wang Y, Si X, Wang T, Wu H, Zhai X, Zhong X, Gao S, Tong L, Xu Z, Zhong Z: AUF1 is recruited to the stress granules induced by coxsackievirus B3. Virus Res. 2014, 192: 52-61. 10.1016/j.virusres.2014.08.003.PubMedView ArticleGoogle Scholar
- Wang L, Qin Y, Tong L, Wu S, Wang Q, Jiao Q, Guo Z, Lin L, Wang R, Zhao W, Zhong Z: MiR-342-5p suppresses coxsackievirus B3 biosynthesis by targeting the 2C-coding region. Antiviral Res. 2012, 93: 270-279. 10.1016/j.antiviral.2011.12.004.PubMedView ArticleGoogle Scholar
- Guo Z, Zhong X, Lin L, Wu S, Wang T, Chen Y, Zhai X, Wang Y, Wu H, Tong L, Han Y, Pan B, Peng Y, Si X, Zhang F, Zhao W, Zhong Z: A 3Cpro-dependent bioluminescence imaging assay for in vivo evaluation of anti-enterovirus 71 agents. Antiviral Res. 2014, 101: 82-92. 10.1016/j.antiviral.2013.11.002.PubMedView ArticleGoogle Scholar
- Wang T, Yu B, Lin L, Zhai X, Han Y, Qin Y, Guo Z, Wu S, Zhong X, Wang Y, Tong L, Zhang F, Si X, Zhao W, Zhong Z: A functional nuclear localization sequence in the VP1 capsid protein of coxsackievirus B3. Virology. 2012, 433: 513-521. 10.1016/j.virol.2012.08.040.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.